Iconovo: The same but different – Danske Bank
Significant market opportunity. Iconovo’s addressable market amounts to c. 500m people suffering from asthma or COPD (chronic obstructive pulmonary disease). The company’s current product portfolio addresses a market worth c.
USD14bn in product sales annually, comprising mainly five approved inhalers (HandiHaler from Boehringer Ingelheim, Breezhaler from Novartis, Advair Diskus and Ellipta inhalers from GSK, and Symbicort Turbuhaler from AstraZeneca). Compared to generic solid oral tablets, the generic market for inhalants is tougher to access due to its high regulatory standards and complexity in drug delivery, combining a drug formulation with an inhaler.